Drug Discovery and One Health Approach in Combating Infectious Diseases: A Multi-sectoral Approach to address Infections explores the intersection of drug discovery and the One Health Approach, along with the effectiveness of interdisciplinary approaches to combating infectious diseases. The book covers both holistic and innovative drug discovery methodologies and technologies such as natural compounds, harnessing genomics, proteomics, and nanotechnology. Additionally, the book reviews zoonotic diseases, vaccine development, ethical considerations, and regulatory pathways. Practice case studies demonstrate successful One Health and interdisciplinary initiatives to combating infectious disease.
This catalogue of knowledge provides a toolbox of innovative and interdisciplinary solutions of complex issues in drug discovery and infectious disease. It will be a valuable resource to professionals and researchers working in the fields of biomedical sciences, pharmaceutical sciences, infectious disease research, and public health, as well as those engaged in drug discovery, development, and the management of infectious diseases.
- Presents practical case studies on successful One Health initiatives
- Provides the fundamentals of drug discovery and the One Health approach through an interdisciplinary lens
- Explains innovative technologies and emerging trends in infectious disease management and drug discovery
Dr. Kanti Bhooshan Pandey is a Principal Scientist and Assistant Professor in the Faculty of Biological Sciences, AcSIR; CSIR-Central Salt and Marine Chemicals Research Institute, Gujarat, India. He is doctorate in Biochemistry. His research expertise includes clinical biochemistry, food biochemistry, molecular cell biology, and Gerontology. He has done significant work on investigation of molecular mechanisms of action of plant-derived polyphenols, a major constituent in food and vital in nutrition point of view. He is working to investigate human aging impairments at molecular level including cellular signaling. He has designed a new protocol in cell biology and investigated a novel mechanism of action of bioactive compounds involved in cellular homeostasis and ascorbate recycling. His findings have found commercial applications. Dr. Pandey is the recipient of many national and international fellowships and has been authored more than 57 research papers and book chapters. He is in the editorial/advisory board of many reputed international journals.
Prof. David J. Newman is currently an NIH Special Volunteer. He holds a research MSc (1963, organic chemistry, Univ. Liverpool, UK), a DPhil (1968, microbiological chemistry, Univ. Sussex UK), followed by a 2 yr post-doc at the Univ. Georgia (USA) on rubredoxin sequencing, and an MLS (1977, Drexel Univ., USA). After the post-doc He spent 15 years at SKF (now GSK) in the US mainly in antibiotic discovery, then six years in smaller companies still in the USA, mainly dealing with marine chemistry and then in 1991 joined the Natural Products Branch of the NCI covering marine and microbial sources as leads to antitumor drugs. When Gordon Cragg retired as Branch Chief at the end of 2004, he became Branch Chief, retiring in early January 2015. He now is an NIH Special Volunteer (honorary position) with the same branch. He has published over 240 papers/chapters, has held adjunct and honorary positions as a full Professor at the University of Maryland (USA) and at MacQuarrie University in Sydney, Australia (still active). He still publishes on natural products mainly from marine and microbial sources. He is currently a Fellow of the Royal Society of Chemistry and a Chartered Chemist, also a Fellow of the Royal Society of Biology and a Chartered Biologist. He is also Fellow of the American Society of Pharmacognosy and last year he was made an honorary member of that society. He is also an emeritus member of both the American Society of Microbiology and the American Chemical Society.
Chukwuebuka Egbuna (PhD) is a chartered chemist and academic researcher. He is a member of the Institute of Chartered Chemists of Nigeria (ICCON), the Nigerian Society of Biochemistry and Molecular Biology (NSBMB), and the Royal Society of Chemistry (RSC) (United Kingdom). Dr. Egbuna is the founder and editor of the Elsevier book series on Drug Discovery Update. The series includes books, monographs, and edited collections from all areas of drug discovery including emerging therapeutic claims for the treatment of diseases. He has published research articles in many international journals of repute and is ranked among the top 500 Nigerian scientists in SciVal/SCOPUS. He has edited more than 25 books with Elsevier, Springer, Wiley, and Taylor & Francis. His most recent book is the three volume Coronavirus Drug Discovery, published by Elsevier. Dr. Egbuna is the founder and the publishing director of IPS Intelligentsia Publishing Services.
